The Latest Cardiac and Vascular News
NEW ORLEANS, LA, JUNE 6, 2025 – Findings from a phase three, randomized controlled clinical trial demonstrate the superiority of Humacyte’s Acellular Tissue Engineered Vessel (ATEV) over autologous arteriovenous fistula (AVF) in high-risk patients with end-stage kidney disease (ESKD). These data highlight the potential of ATEV to address unmet needs […]
ALAMEDA, Calif., June 5, 2025 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more…
PITTSBURGH, June 4, 2025 /PRNewswire/ – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for rapid detection of infection causing bacteria in wounds, is pleased to announce its participation in the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM),…
San Clemente, CA – May 29, 2025 – Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System a unique clinical solution for the treatment of […]
AV Access Study to be Presented at the Vascular Annual Meeting (VAM25) AV Access Study to be Presented at the Vascular Annual Meeting (VAM25)
– Innovative, dual-layer micromesh, closed-cell stent with the flexibility of an open-cell stent for maximizing clinical outcomes in carotid artery stenting procedures – SOMERSET, N.J., May 27, 2025 /PRNewswire/ — Terumo Interventional Systems (TIS), a division of Terumo Corporation, is…
HANGZHOU, China, May 26, 2025 /PRNewswire/ — Zylox-Tonbridge Medical Technology Co., Ltd. (“Zylox-Tonbridge” or the “Company”) today announced that its proprietary ZYLOX Unicorn™ Vascular Closure Device (VCD) has received regulatory approval in Indonesia. This marks the ZYLOX Unicorn™…
MINNEAPOLIS, May 22, 2025 /PRNewswire/ — Phraxis Inc., a Minneapolis-based medical device company, marks a major milestone with FDA approval of the EndoForce™ Connector for Endovascular Venous Anastomosis (EndoForce™) — a pivotal development in the evolution of dialysis access technology….
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.
AUCKLAND, New Zealand, May 1, 2025 /PRNewswire/ — Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence. There are now over 100 peer-reviewed studies describing the efficacy of the company’s proprietary AROA ECM technology. AROA’s most…
